Research Efforts Underway for RARA+ MDS and AML

Ana Alfonso Piérola, MD, PhD, discusses the rationale for targeting retinoic acid receptor alpha in patients with higher-risk myelodysplastic syndrome, the goals of the SELECT MDS-1 trial investigating tamibarotene, and where the future of research and treatment for this patient population is headed.

Brian Ball, MD, discusses the significance of targeting RARA in AML, the rationale for SELECT-AML-1, and additional AML research that may contribute to the broadening treatment paradigm in the future.

Ana Alfonso Piérola, MD, PhD, discusses unmet needs for patients with high-risk myelodysplastic syndrome.

Giovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.

Gautam Borthakur, MD, discussed the rationale for targeting RARA-overexpressing AML, the potential efficacy and safety benefits of tamibarotene, and how SELECT AML-1 and SELECT MDS-1 could change the respective treatment landscapes in AML and MDS.

Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.

Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.

Daniel Pollyea, MD, MS, reviews the ongoing SELECT-AML-1 trial and comments on novel therapies and biomarkers in patients with newly diagnosed unfit AML.

Risk stratification for patients with myelodysplastic syndrome have afforded those with asymptomatic or low-risk disease treatment pathways that can be navigated using a variety of patient characteristics. However, treatment algorithms for patients with higher-risk disease are limited to allogeneic transplant or treatment with hypomethylating agents.

Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.

Dr Daniel Pollyea discusses the role of venetoclax plus an HMA agent in patients with AML and talks about some possible mechanisms of resistance to the venetoclax-HMA combination.

Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.

Daniel Pollyea, MD, MS, reviews the initial results from the biomarker-directed phase 2 tamibarotene trial that were presented at ASH 2020.

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

Hetty Carraway, MD, discusses the role of biomarker testing in patients with myelodysplastic syndromes and acute myeloid leukemia.

Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.

Dr Daniel Pollyea comments on biomarker testing in acute myeloid leukemia and the potential role for RARA testing.

An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.

A review of treatment options for patients with newly diagnosed acute myeloid leukemia and differences between patients who are fit vs unfit for chemotherapy.

Eytan M. Stein, MD, discusses the phase 2 SELECT-AML-1 trial in patients with newly diagnosed acute myeloid leukemia.

Afaf E. Osman, MD, discusses the phase 3 SELECT-MDS trial in patients with higher-risk myelodysplastic syndrome.